Abrogation of Rb pathway function is frequent in breast tumors by loss of expression of Rb or altered expression of inhibitors of Rb activity (e.g. loss/silencing of CDKN2A (p16) and amplification and/or over expression of CCND1, CDK4, CDK6) (Figure 7). This evidence concerns the gene RB1 and breast neoplasm.